MediciNova (MNOV) Completes Phase 2 Trial of MN-001 for Diabetic Liver Disease

MediciNova, Inc. (NASDAQ: MNOV) concluded a Phase 2 clinical trial of MN-001 in patients with diabetic non-alcoholic fatty liver disease (NAFLD) on May 27, 2026. The study assessed the oral drug's safety and efficacy in reducing liver fat and fibrosis among individuals with type 2 diabetes. Top-line data are expected in the coming months, with detailed results to be presented at a future medical conference. MN-001 is an anti-inflammatory and anti-fibrotic small molecule targeting key pathways in NAFLD progression. The company will determine Phase 3 development plans following a full analysis of the trial outcomes.